Literature DB >> 21822237

Biosimilars-why terminology matters.

Martina Weise, Marie-Christine Bielsky, Karen De Smet, Falk Ehmann, Niklas Ekman, Gopalan Narayanan, Hans-Karl Heim, Esa Heinonen, Kowid Ho, Robin Thorpe, Camille Vleminckx, Meenu Wadhwa, Christian K Schneider.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21822237     DOI： 10.1038/nbt.1936

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  8 in total

1.  FDA notifications. FDA uncovers counterfeit Procrit.

Authors: 
Journal:  AIDS Alert       Date:  2003-06

2.  Characterizing biological products and assessing comparability following manufacturing changes.

Authors:  Arthur J Chirino; Anthony Mire-Sluis
Journal:  Nat Biotechnol       Date:  2004-11       Impact factor: 54.908

Review 3.  Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.

Authors:  Christian Combe; Roger L Tredree; Huub Schellekens
Journal:  Pharmacotherapy       Date:  2005-07       Impact factor: 4.705

4.  Biosimilar low molecular weight heparin products.

Authors:  E Gray; B Mulloy
Journal:  J Thromb Haemost       Date:  2009-04-24       Impact factor: 5.824

5.  Pure red cell aplasia due to follow-on epoetin.

Authors:  Sai Ram Keithi-Reddy; Sadayandi Kandasamy; Ajay K Singh
Journal:  Kidney Int       Date:  2008-06-11       Impact factor: 10.612

6.  Biosimilars: illustration of scientific issues in two examples.

Authors:  Richard G Wenzel
Journal:  Am J Health Syst Pharm       Date:  2008-07-15       Impact factor: 2.637

7.  Impact of illegal trade on the quality of epoetin alfa in Thailand.

Authors:  Fotis Fotiou; Suresh Aravind; Ping-Ping Wang; Osot Nerapusee
Journal:  Clin Ther       Date:  2009-02       Impact factor: 3.393

8.  Biosimilar therapeutics-what do we need to consider?

Authors:  Huub Schellekens
Journal:  NDT Plus       Date:  2009-01
  8 in total
  41 in total

1.  7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.

Authors:  Alexey A Lugovskoy; Janice M Reichert; Alain Beck
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Comment on: "EU's new pharmacovigilance legislation: considerations for biosimilars".

Authors:  John Joseph Borg; Anthony Serracino-Inglott; Lilian M Azzopardi; Christian K Schneider
Journal:  Drug Saf       Date:  2014-02       Impact factor: 5.606

3.  Different pharmaceutical products need similar terminology.

Authors:  Daan J A Crommelin; Jon S B de Vlieger; Vera Weinstein; Stefan Mühlebach; Vinod P Shah; Huub Schellekens
Journal:  AAPS J       Date:  2013-09-25       Impact factor: 4.009

4.  Biosimilars: Implications for health-system pharmacists.

Authors:  Steven D Lucio; James G Stevenson; James M Hoffman
Journal:  Am J Health Syst Pharm       Date:  2013-11-15       Impact factor: 2.637

Review 5.  Biosimilar: what it is not.

Authors:  Fernando de Mora
Journal:  Br J Clin Pharmacol       Date:  2015-06-04       Impact factor: 4.335

6.  Setting the stage for biosimilar monoclonal antibodies.

Authors:  Christian K Schneider; Camille Vleminckx; Iordanis Gravanis; Falk Ehmann; Jean-Hugues Trouvin; Martina Weise; Steffen Thirstrup
Journal:  Nat Biotechnol       Date:  2012-12       Impact factor: 54.908

7.  Efficacy and safety of biosimilar filgrastim in primary and secondary prevention of febrile neutropenia.

Authors:  Leszek Kraj; Joanna Krawczyk-Lipiec; Joanna Górniewska; Grzegorz Orlik
Journal:  Biomed Rep       Date:  2017-07-04

8.  Barriers to the uptake of biosimilars and possible solutions: a Belgian case study.

Authors:  Pieter Dylst; Arnold Vulto; Steven Simoens
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

Review 9.  The emergence of biosimilar insulin preparations--a cause for concern?

Authors:  David R Owens; Wolfgang Landgraf; Andrea Schmidt; Reinhard G Bretzel; Martin K Kuhlmann
Journal:  Diabetes Technol Ther       Date:  2012-10-09       Impact factor: 6.118

Review 10.  State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.

Authors:  Adrian Covic; Ivo Abraham
Journal:  Int Urol Nephrol       Date:  2015-07-30       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.